Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity

Journal of Neural Transmission

Volumn 116, Issue 5, 2009, Pages 579-585

  Müller, Kerstin ^a,b   Mix, Eilhard ^a   Saberi, Fereshte Adib ^c   Dressler, Dirk ^d   Benecke, Reiner ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b Appenzell Ausserrhoden ^*  (Switzerland)

^c Asklepios Klinik Nord Heidberg   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Antibodies; Botulinum toxin; Mouse diaphragm assay; Spasticity

Indexed keywords

BOTULINUM TOXIN A; NEUTRALIZING ANTIBODY; TOXIN ANTIBODY;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CEREBRAL PALSY; CERVICAL DYSTONIA; DRUG RESPONSE; FEMALE; HUMAN; MALE; MOUSE DIAPHRAGM ASSAY; PREVALENCE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; SPASTICITY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANIMALS; ANTIBODIES; BIOLOGICAL ASSAY; BOTULINUM TOXIN TYPE A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MICE; MIDDLE AGED; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 67349087709     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-009-0223-z     Document Type: Article

References (30)

1. MZ Atassi 2004 Basic immunological aspects of botulinum toxin therapy Mov Disord 19 Suppl 8 S68 S84
2. AM Bakheit AF Thilmann AB Ward W Poewe J Wissel J Müller R Benecke C Collin F Müller CD Ward C Neumann 2000 A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke Stroke 31 2402 2406
3. AM Bakheit S Pittock AP Moore M Wurker S Otto F Erbguth L Coxon 2001 A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin A in upper limb spasticity in patients with stroke Eur J Neurol 8 559 565
4. BB Bhakta JA Cozens JM Bamford MA Chamberlain 1996 Use of botulinum toxin in stroke patients with severe upper limb spasticity J Neurol Neurosurg Psychiat 61 30 35 (Pubitemid 26232024)
5. BB Bhakta JA Cozens MA Chamberlain JM Bamford 2000 Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial J Neurol Neurosurg Psychiat 69 217 221 (Pubitemid 30466027)
6. A Brashear MF Gordon E Elovic VD Kassicieh C Marciniak M Do CH Lee S Jenkins C Turkel Botox Post-Stroke Spasticity Study Group 2002 Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke N Engl J Med 347 395 400
7. CP Das D Dressler M Hallett 2006 Botulinum toxin therapy of writer's cramp Eur J Neurol 13 Suppl 1 55 59
8. D Dressler H Bigalke 2002 Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy Mov Disord 17 170 173 (Pubitemid 36041275)
9. D Dressler G Dirnberger 2001 Botulinum toxin antibody testing: comparison between the immunoprecipitation assay and the mouse diaphragm assay Eur Neurol 45 257 260 (Pubitemid 32521045)
10. D Dressler M Hallett 2006 Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc Eur J Neurol 13 Suppl 1 11 15
11. MF Gordon A Brashear E Elovic D Kassicieh C Marciniak J Liu C Turkel BOTOX Poststroke Spasticity Study Group 2004 Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke Neurology 63 1971 1973 (Pubitemid 39532408)
12. H Göschel K Wohlfarth J Frevert R Dengler H Bigalke 1997 Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies-therapeutic consequences Exp Neurol 147 96 102 (Pubitemid 27402446)
13. PA Hanna J Jankovic A Vincent 1999 Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies J Neurol Neurosurg Psychiat 66 612 616 (Pubitemid 29186967)
14. J Herrmann K Geth V Mall H Bigalke J Schulte Monting M Linder J Kirschner S Berweck R Korinthenberg F Heinen UM Fietzek 2004 Clinical impact of antibody formation to botulinum toxin A in children Ann Neurol 55 732 735 (Pubitemid 38544335)
15. S Hesse C Werner 2003 Poststroke motor dysfunction and spasticity: novel pharmacological and physical treatment strategies CNS Drugs 17 1093 1107 (Pubitemid 38021395)
16. J Jankovic KD Vuong J Ahsan 2003 Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia Neurology 60 1186 1188 (Pubitemid 36418786)
17. KR Kessler R Benecke 1997 The EBD test-a clinical test for the detection of antibodies to botulinum toxin type A Mov Disord 12 95 99 (Pubitemid 27032886)
18. KR Kessler M Skutta R Benecke 1999 Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group J Neurol 246 265 274 (Pubitemid 29229352)
19. MH Marion M Sheehy S Sangla S Soulayrol 1995 Dose standardisation of botulinum toxin J Neurol Neurosurg Psychiatry 59 102 103
20. AP Moore 2002 Botulinum toxin A (BoNT-A) for spasticity in adults. What is the evidence? Eur J Neurol 9 Suppl 1 42 47 (Pubitemid 41759600)
21. M Naumann A Albanese F Heinen G Molenaers M Relja 2006 Safety and efficacy of botulinum toxin type A following long-term use Eur J Neurol 13 Suppl 4 35 40 (Pubitemid 44748282)
22. MS Pathak HT Nguyen HK Graham AP Moore 2006 Management of spasticity in adults: practical application of botulinum toxin Eur J Neurol 13 Suppl 1 42 50
23. SJ Pittock AP Moore O Hardiman E Ehler M Kovac J Bojakowski I Al Khawaja M Brozman P Kanovsky A Skorometz J Slawek G Reichel A Stenner S Timerbaeva Z Stelmasiak UA Zifko B Bhakta E Coxon 2003 A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus + deformity after stroke Cerebrovasc Dis 15 289 300 (Pubitemid 36438734)
24. RL Rosales AS Chua-Yap 2008 Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity J Neural Transm 115 617 623
25. RL Rosales H Bigalke D Dressler 2006 Pharmacology of botulinum toxin: differences between type A preparations Eur J Neurol 13 Suppl 1 2 10
26. D Sesardic RG Jones T Leung T Alsop R Tierney 2004 Detection of antibodies against botulinum toxins Mov Disord 19 Suppl 8 S85 S91
27. AB Ward 2008 Spasticity treatment with botulinum toxins J Neural Transm 115 607 616
28. K Wohlfarth H Göschel J Frevert R Dengler H Bigalke 1997 Botulinum A toxins: units versus units Naunyn-Schmiedeberg's Arch Pharmacol 355 335 340 (Pubitemid 27117590)
29. K Wohlfarth I Schwandt F Wegner T Jürgens G Gelbrich A Wagner U Bogdahn W Schulte-Mattler 2008 Biological activity of two botulinum toxin type A complexes (Dysport and Botox) in volunteers: a double-blind, randomized, dose-ranging study J Neurol 255 1932 1939
30. SA Yablon A Brashear MF Gordon EP Elovic CC Turkel S Daggett J Liu MF Brin 2007 Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials Clin Ther 29 683 690 (Pubitemid 47016643)